The REDEFINE 3 cardiovascular outcomes trial which will take several years to complete is not a prerequisite for initial market authorisation for obesity treatment, but its results will likely be important for subsequent label expansion and for establishing the cardiovascular benefit profile that has proven so valuable for tirzepatide and semaglutide
Monnier M, Dudler L, Gchter R, Maier PF, Tobler HJ, Schoenenberger GA
In animal models, gene therapy has produced encouraging results, particularly concerning ABCB4, whether through vectors expressing ABCB4 or by focusing on the disease mechanism [98]
No published RCT has tested topical or systemic GHK-Cu for GSM or FSD, but NAMS guidelines (2020) acknowledge that vascular and structural restoration of vaginal tissue is a legitimate therapeutic goal
Whether you are exploring glutathione as a standalone IV or as an add on to another infusion, we prioritize transparency, safety, and individualized care
a short loading phase may be followed by spaced maintenance or a switch to oral therapy